Tarloxitinib puts tumor-seeking tail on anti-EGFR drug to precisely target lung cancer
EGFR is a common genetic target in lung cancer, but not all EGFR mutations are created equal. Patients with a type of EGFR anomaly called an "EGFR exon 20 insertion" often fail to respond to existing drugs targeting EGFR. ...
Oct 24, 2017